She joins in August, replacing Amie Malkin, who last week moved to AstraZeneca as head of comms after 12 years with BM (PRWeek, 25 April).
MS&L’s health practice had a turbulent time last year, with several senior players – including head of international healthcare Carolyn Brown and long-serving health director Sally Bradford – leaving.
However, things have appeared calmer since the appointment of head of healthcare Peter Carr at the end of 2006.
Garratt, who was working primarily on global accounts at MS&L, such as Sanofi-Aventis’ anti-obesity drug Acomplia, has academic as well as comms credentials, with a PhD in pharmacology. She is expected to initially focus on BM’s work for the REACH registry, an international study to determine how people are affected by atherothrombosis.
BM chief executive Jonathan Jordan said: ‘Jennifer has experience in med ed and PR, and has a very strong scientific background. Her track record for strategic client counsel and team building made her an obvious choice for us.’
As well as the attraction of the more senior role, Garratt said that she was keen to work in med ed as well as PR again, as she had as a director at Avenue HKM. She joined MS&L two years ago from Avenue, prior to which she was at Blackwell Healthcare.
Tessa Hopkins, who has been working with BM in an interim MD role since last autumn, will continue working at the agency for the foreseeable future, said Jordan.